Investing Insights: CRISPR and Amgen Near 52-Week Lows

Investors should consider CRISPR Therapeutics and Amgen, both hovering near their 52-week lows. The potential growth in CRISPRs pipeline and Amgen's strong revenue performance offers a promising outlook.

Date: 16-01-2025

AI Rating: 7

Overview of Investment Opportunities: The report discusses two biotech companies, CRISPR Therapeutics and Amgen, that have recently struggled but are now seen as potential investment opportunities. Both are near their 52-week lows, which might prompt investors to take a closer look at their fundamentals.

CRISPR Therapeutics: The company has a single product, Casgevy, in the market but is currently not generating revenue and remains unprofitable. The report highlights that while CRISPR does not have revenue currently, it has substantial market potential with an estimated peak sales of over $1 billion, driven by a total target patient population of at least 58,000. Additionally, the FDA’s granting of RMAT designation to CTX112 is a significant milestone that could enhance the company’s prospects. However, the risk factors related to the company's unproven pipeline and current lack of revenue could deter more conservative investors.

Amgen: In contrast, Amgen has posted impressive results, particularly a 23% year-over-year revenue growth to $8.5 billion in the third quarter. This growth stems from both acquisitions and organic sales. The company is working on further developments to expand its product offerings, especially with MariTide and Tepezza, which could enhance long-term revenue streams. The report notes the company’s strong financials, with factors such as a history of significant dividend increases and a current yield of 3.63%, appealing to income-focused investors.

In summary, while CRISPR offers high-risk, high-reward potential in emerging biotech markets, Amgen presents a more stable investment with strong revenue growth and a track record of dividend payments.

Stocks: CRSP AMGN